192 related articles for article (PubMed ID: 22028822)
21. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses.
Horton JK; Stefanick DF; Gassman NR; Williams JG; Gabel SA; Cuneo MJ; Prasad R; Kedar PS; Derose EF; Hou EW; London RE; Wilson SH
DNA Repair (Amst); 2013 Sep; 12(9):774-85. PubMed ID: 23871146
[TBL] [Abstract][Full Text] [Related]
22. Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis.
McGurk L; Mojsilovic-Petrovic J; Van Deerlin VM; Shorter J; Kalb RG; Lee VM; Trojanowski JQ; Lee EB; Bonini NM
Acta Neuropathol Commun; 2018 Aug; 6(1):84. PubMed ID: 30157956
[TBL] [Abstract][Full Text] [Related]
23. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
24. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
[TBL] [Abstract][Full Text] [Related]
25. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.
Zaremba T; Thomas HD; Cole M; Coulthard SA; Plummer ER; Curtin NJ
Biochem J; 2011 Jun; 436(3):671-9. PubMed ID: 21434873
[TBL] [Abstract][Full Text] [Related]
26. In vitro effects of poly(ADP-ribose) polymerase inhibitors on the production of tumor necrosis factor-α by interferon- γ - and lipopolysaccharide-stimulated peripheral blood mononuclear cells of horses.
Cacciolatti C; Meyer-Ficca ML; Southwood LL; Meyer RG; Bertolotti L; Zarucco L
Am J Vet Res; 2019 Jul; 80(7):663-669. PubMed ID: 31246122
[TBL] [Abstract][Full Text] [Related]
27. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Redon CE; Nakamura AJ; Zhang YW; Ji JJ; Bonner WM; Kinders RJ; Parchment RE; Doroshow JH; Pommier Y
Clin Cancer Res; 2010 Sep; 16(18):4532-42. PubMed ID: 20823146
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Schaefer NG; James E; Wahl RL
Nucl Med Commun; 2011 Nov; 32(11):1046-51. PubMed ID: 21956491
[TBL] [Abstract][Full Text] [Related]
29. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
[TBL] [Abstract][Full Text] [Related]
30. PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels.
Boudra MT; Bolin C; Chiker S; Fouquin A; Zaremba T; Vaslin L; Biard D; Cordelières FP; Mégnin-Chanet F; Favaudon V; Fernet M; Pennaneach V; Hall J
Cell Mol Life Sci; 2015 Apr; 72(8):1585-97. PubMed ID: 25336152
[TBL] [Abstract][Full Text] [Related]
31. Quantification of cellular poly(ADP-ribosyl)ation by stable isotope dilution mass spectrometry reveals tissue- and drug-dependent stress response dynamics.
Martello R; Mangerich A; Sass S; Dedon PC; Bürkle A
ACS Chem Biol; 2013 Jul; 8(7):1567-75. PubMed ID: 23631432
[TBL] [Abstract][Full Text] [Related]
32. Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation.
Yamashita S; Tanaka M; Ida C; Kouyama K; Nakae S; Matsuki T; Tsuda M; Shirai T; Kamemura K; Nishi Y; Moss J; Miwa M
Exp Cell Res; 2022 Aug; 417(1):113163. PubMed ID: 35447104
[TBL] [Abstract][Full Text] [Related]
33. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Liu X; Shi Y; Guan R; Donawho C; Luo Y; Palma J; Zhu GD; Johnson EF; Rodriguez LE; Ghoreishi-Haack N; Jarvis K; Hradil VP; Colon-Lopez M; Cox BF; Klinghofer V; Penning T; Rosenberg SH; Frost D; Giranda VL; Luo Y
Mol Cancer Res; 2008 Oct; 6(10):1621-9. PubMed ID: 18922977
[TBL] [Abstract][Full Text] [Related]
34. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
35. Quantification of PARP Activity in Human Tissues: Ex Vivo Assays in Blood Cells and Immunohistochemistry in Human Biopsies.
Horvath EM; Zsengellér ZK; Szabo C
Methods Mol Biol; 2017; 1608():19-26. PubMed ID: 28695500
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
Pfister TD; Hollingshead M; Kinders RJ; Zhang Y; Evrard YA; Ji J; Khin SA; Borgel S; Stotler H; Carter J; Divelbiss R; Kummar S; Pommier Y; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2012; 7(12):e50494. PubMed ID: 23284638
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo supplementation with nicotinic acid enhances cellular poly(ADP-ribosyl)ation and improves cell viability in human peripheral blood mononuclear cells.
Weidele K; Kunzmann A; Schmitz M; Beneke S; Bürkle A
Biochem Pharmacol; 2010 Oct; 80(7):1103-12. PubMed ID: 20599792
[TBL] [Abstract][Full Text] [Related]
38. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Shibata H; Miuma S; Saldivar JC; Huebner K
Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
40. FUS RRM regulates poly(ADP-ribose) levels after transcriptional arrest and PARP-1 activation on DNA damage.
Mamontova EM; Clément MJ; Sukhanova MV; Joshi V; Bouhss A; Rengifo-Gonzalez JC; Desforges B; Hamon L; Lavrik OI; Pastré D
Cell Rep; 2023 Oct; 42(10):113199. PubMed ID: 37804508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
